Secondary Organising Pneumonia Among Immunocompromised Multiple Sclerosis Patients Treated With Ocrelizumab Following COVID‐19 Infection: Two Case Reports With Literature Review
ABSTRACT Anti‐CD20 medications, such as rituximab and coronavirus disease 2019 (COVID‐19) infection, have been shown to cause secondary organising pneumonia (OP). Ocrelizumab is an anti‐CD20 monoclonal antibody widely used as a disease‐modifying therapy for relapsing–remitting and primary progressiv...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.70268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|